Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN
Depomed receives final meeting minutes from FDA for pre-NDA meeting on DM-1796 for PHN
Depomed, Inc. today announced that it has received final meeting minutes from the FDA for a pre-NDA meeting related to DM-1796 for postherpetic neuralgia (PHN) held in December 2009. Depomed also commented on recent public disclosures related to the Complete Response letter from the U.S. Food and Drug Administration regarding the New Drug Application (NDA) for Horizant™ (gabapentin enacarbil …
Read more on News-Medical-Net
